Peter Koelblinger

Salzburg, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 57 publications

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026.

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026.

Journal: European journal of cancer (Oxford, England : 1990)
Published: March 19, 2026

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.

Journal: European journal of cancer (Oxford, England : 1990)
Published: March 19, 2026

Ropeginterferon-α2b in mycosis fungoides and Sézary syndrome: Safety and efficacy in 41 patients.

Ropeginterferon-α2b in mycosis fungoides and Sézary syndrome: Safety and efficacy in 41 patients.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Published: January 23, 2026

Eyelid nodule with persistent growth.

Eyelid nodule with persistent growth.

Journal: JAAD case reports
Published: October 13, 2025

Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.

Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.

Journal: Nature medicine
Published: September 12, 2025

Indoor tanning: Smoking for the skin.

Indoor tanning: Smoking for the skin.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: September 12, 2025

Adjuvant immune-checkpoint inhibition in melanoma: How long do we really need to treat?

Adjuvant immune-checkpoint inhibition in melanoma: How long do we really need to treat?

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 26, 2025

Acyl-CoA synthetase long-chain family member 4-A novel prognostic marker in cutaneous melanoma.

Acyl-CoA synthetase long-chain family member 4-A novel prognostic marker in cutaneous melanoma.

Journal: Frontiers in medicine
Published: December 31, 2024

Therapeutic Approaches for Advanced Basal Cell Carcinoma: A Comprehensive Review.

Therapeutic Approaches for Advanced Basal Cell Carcinoma: A Comprehensive Review.

Journal: Cancers
Published: November 04, 2024

Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy.

Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 07, 2024

The discrepancy between managing the disease and a disease management program in systemic melanoma therapy.

The discrepancy between managing the disease and a disease management program in systemic melanoma therapy.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
Published: May 02, 2024

Immune checkpoint inhibitor-induced pancreatic enzyme elevation in melanoma patients: Incidence, management and therapy-A multicentre analysis.

Immune checkpoint inhibitor-induced pancreatic enzyme elevation in melanoma patients: Incidence, management and therapy-A multicentre analysis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: April 18, 2024
Showing 1-12 of 57

Last Updated: 09/26/2026